DAN

Dana Q3 2024 – Sales Down, Net Income Drops, Shares Plummet

Dana Incorporated has reported its financial results for the third quarter of 2024, with sales totaling $2.48 billion, a decrease from the $2.67 billion reported in the same period of 2023. The company's net income for the third quarter of 2024 was $4 million, down from $19 million in the third quarter of 2023.

Adjusted EBITDA for the third quarter of 2024 was $232 million, representing a 30-basis-point improvement in adjusted EBITDA margin compared to the same period in 2023. However, the adjusted net income attributable to Dana was $18 million, and diluted adjusted earnings per share were $0.12 for the third quarter of 2024, down from adjusted net income of $43 million and $0.30 per share in 2023.

Operating cash flow in the third quarter of 2024 was $35 million, a decrease from the $112 million reported in the same period of 2023. Additionally, free cash flow was a use of $11 million, compared with a use of $5 million for the third quarter of 2023.

Looking ahead, Dana has revised its 2024 financial targets, now expecting sales of $10.2 to $10.4 billion, adjusted EBITDA of $855 to $895 million, operating cash flow of approximately $465 to $485 million, and free cash flow of $90 to $110 million. The company has also provided diluted EPS guidance of $0.05 to $0.25, and diluted adjusted EPS of $0.75 to $0.95.

Despite lower sales and profit expectations for the remainder of the year due to reduced end-market demand, Dana remains focused on driving profitability and cash flow improvements.

The company will be hosting a conference call on Wednesday, October 30, to discuss its third-quarter results in more detail. Following these announcements, the company's shares moved -15.9%, and are now trading at a price of $8.53. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS